Why the study?
Cardiovascular diseases are increasingly attributed to exacerbated inflammatory responses, highlighting the lymphatic system's role in immune cell surveillance and trafficking as a potential therapeutic target.
Key points are not available for this paper at this time.
Design
Review
Lymphatic involvement in CVD inflammation merits targeted study; leaves open whether modulation alters clinical outcomes.
Cardiovascular diseases remain the largest cause of death worldwide with recent evidence increasingly attributing the development and progression of these diseases to an exacerbated inflammatory response. As a result, significant research is now focused on modifying the immune environment to prevent the disease progression. This in turn has highlighted the lymphatic system in the pathophysiology of cardiovascular diseases owing, in part, to its established function in immune cell surveillance and trafficking. In this review, we highlight the role of the cardiac lymphatic system and its potential as an immunomodulatory therapeutic target in selected cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Cooper et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: